Therefore, the increase or decrease of PD-L1 expression in the tumor microenvironment may affect the efficacy of anti-PD-1/PD-L1 therapy, which can be explained by different immune evasion mechanisms. The gene discussed is PDCD1; the disease is neoplasm.